Seres Therapeutics
MCRB
MCRB
80 hedge funds and large institutions have $237M invested in Seres Therapeutics in 2018 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 27 increasing their positions, 31 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
13% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 31
27% less capital invested
Capital invested by funds: $326M → $237M (-$88.3M)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
Holders
80
Holding in Top 10
1
Calls
$809K
Puts
$131K
Top Buyers
| 1 | +$5.73M | |
| 2 | +$1.98M | |
| 3 | +$1.19M | |
| 4 |
Morgan Stanley
New York
|
+$664K |
| 5 |
VEA
Virtus ETF Advisers
New York
|
+$304K |
Top Sellers
| 1 | -$3.04M | |
| 2 | -$1.56M | |
| 3 | -$1.54M | |
| 4 |
O
OrbiMed
New York
|
-$912K |
| 5 |
JPMorgan Chase & Co
New York
|
-$783K |